As fusion advances, the distinction between scientific progress and commercial readiness is narrowing. The focus is shifting to which milestones demonstrate not just performance, but a credible, financeable path to integrated systems and deployment.

• What short-term milestones will signal credible progress toward commercial fusion?
• Which milestones most reduce risk and unlock follow-on investment?
• What capital requirements do different fusion approaches face on the path to pilot plants and first commercial power?
• How do companies best translate plasma performance, neutron production, and subsystem validation into compelling investment cases?

Moderated by: Matthew Munderville, Program Director, PSFC

Participants include: